Crystalvue Medical Corporation (TPEX:6527)
Taiwan
· Delayed Price · Currency is TWD 75.50
-1.50 (-1.95%)
At close: Mar 9, 2026
Crystalvue Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 949.05 | 868.03 | 823.96 | 795.46 | 721.61 | Upgrade
|
| Revenue Growth (YoY) | 9.33% | 5.35% | 3.58% | 10.23% | 43.07% | Upgrade
|
| Cost of Revenue | 617.17 | 568.89 | 557.22 | 533.71 | 510.22 | Upgrade
|
| Gross Profit | 331.88 | 299.14 | 266.75 | 261.74 | 211.39 | Upgrade
|
| Selling, General & Admin | 110.68 | 108.48 | 104.4 | 89.97 | 73.73 | Upgrade
|
| Research & Development | 40.25 | 45.66 | 44.67 | 46.97 | 49.2 | Upgrade
|
| Operating Expenses | 150.93 | 154.14 | 149.07 | 136.94 | 122.93 | Upgrade
|
| Operating Income | 180.95 | 145.01 | 117.68 | 124.8 | 88.47 | Upgrade
|
| Interest Expense | -0.45 | -0.63 | -0.82 | -1 | -1.17 | Upgrade
|
| Interest & Investment Income | 2.23 | 2.14 | 1.47 | 0.47 | 1.06 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 6.33 | 1.19 | 10.68 | -2.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.71 | 6.53 | 0.22 | 7.48 | 8.97 | Upgrade
|
| EBT Excluding Unusual Items | 179.01 | 159.38 | 119.74 | 142.44 | 95.22 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 13.95 | Upgrade
|
| Pretax Income | 179.01 | 159.38 | 119.74 | 142.44 | 109.17 | Upgrade
|
| Income Tax Expense | 32.03 | 32.23 | 16.34 | 27.41 | 31.93 | Upgrade
|
| Net Income | 146.98 | 127.15 | 103.4 | 115.03 | 77.24 | Upgrade
|
| Net Income to Common | 146.98 | 127.15 | 103.4 | 115.03 | 77.24 | Upgrade
|
| Net Income Growth | 15.59% | 22.98% | -10.11% | 48.93% | 36.42% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 26 | 26 | 25 | 26 | 25 | Upgrade
|
| Shares Change (YoY) | 0.38% | 1.64% | -0.91% | 0.53% | -0.99% | Upgrade
|
| EPS (Basic) | 5.80 | 5.02 | 4.13 | 4.59 | 3.08 | Upgrade
|
| EPS (Diluted) | 5.70 | 4.95 | 4.09 | 4.51 | 3.05 | Upgrade
|
| EPS Growth | 15.15% | 21.03% | -9.31% | 47.98% | 37.93% | Upgrade
|
| Free Cash Flow | -44.98 | 22.62 | 149.64 | 44.24 | -287.91 | Upgrade
|
| Free Cash Flow Per Share | -1.74 | 0.88 | 5.92 | 1.73 | -11.35 | Upgrade
|
| Dividend Per Share | - | 2.250 | 2.070 | 2.286 | 1.848 | Upgrade
|
| Dividend Growth | - | 8.70% | -9.44% | 23.71% | 38.57% | Upgrade
|
| Gross Margin | 34.97% | 34.46% | 32.37% | 32.91% | 29.29% | Upgrade
|
| Operating Margin | 19.07% | 16.71% | 14.28% | 15.69% | 12.26% | Upgrade
|
| Profit Margin | 15.49% | 14.65% | 12.55% | 14.46% | 10.70% | Upgrade
|
| Free Cash Flow Margin | -4.74% | 2.61% | 18.16% | 5.56% | -39.90% | Upgrade
|
| EBITDA | 198.76 | 165.75 | 139.51 | 143.92 | 122.55 | Upgrade
|
| EBITDA Margin | 20.94% | 19.10% | 16.93% | 18.09% | 16.98% | Upgrade
|
| D&A For EBITDA | 17.82 | 20.75 | 21.83 | 19.11 | 34.09 | Upgrade
|
| EBIT | 180.95 | 145.01 | 117.68 | 124.8 | 88.47 | Upgrade
|
| EBIT Margin | 19.07% | 16.71% | 14.28% | 15.69% | 12.26% | Upgrade
|
| Effective Tax Rate | 17.89% | 20.22% | 13.65% | 19.25% | 29.25% | Upgrade
|
| Advertising Expenses | - | - | - | - | 26.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.